Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Volume: 377, Issue: 14, Pages: 1345 - 1356
Published: Sep 11, 2017
Abstract
BackgroundNivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. MethodsWe randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus...
Paper Details
Title
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Published Date
Sep 11, 2017
Volume
377
Issue
14
Pages
1345 - 1356
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.